Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06351332 · ClinicalTrials.gov registry record · Phase 1
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
A Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Filipa Lynce, MD.
- Active
- Registry status
- Phase 1
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT06351332: Active Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, sponsored by Filipa Lynce, MD.
NCT06351332 is a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer that is active but no longer recruiting, run by Filipa Lynce, MD. The registered enrollment target is 78 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06351332, a Phase 1 study of Breast Cancer and Triple Negative Breast Cancer, is active but no longer recruiting, sponsored by Filipa Lynce, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a type of WEE1 inhibitor) * Carboplatin (a type of platinum compound) * Pembrolizumab (a type of monoclonal antibody)
Primary Outcome
Detailed DLT consideration outline in protocol section 5.4. Toxicities are to be assess according to the CTCAE v5. Management and dose modifications associated with the above adverse events outlined in protocol section 6.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Carboplatin
- DRUG Azenosertib
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2029-09-01 |
| Phase | Phase 1 |
What the registry record for NCT06351332 still lists
NCT06351332 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Pembrolizumab is the first listed.
NCT06351332 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06351332 about?
NCT06351332 is a clinical study titled "ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC". This research is being done to evaluate the safety and effectiveness of a drug currently known as Azenosertib (ZN-C3) in combination with the drugs carboplatin and pembrolizumab in metastatic triple-negative breast cancer. The names of the study drugs involved in this study are: * Azenosertib (a t...
What is the current status of trial NCT06351332?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 78 participants. The study started on 2024-05-01. Estimated completion is 2029-09-01.
What conditions does trial NCT06351332 study?
This clinical trial studies the following conditions: Breast Cancer, Triple Negative Breast Cancer, HER2-Negative Breast Cancer, Breast Cancer Female, Hormone Receptor Negative Malignant Tumor Breast Triple.
What interventions are being tested in trial NCT06351332?
The interventions under investigation include: Pembrolizumab (DRUG), Carboplatin (DRUG), Azenosertib (DRUG).
Who is sponsoring clinical trial NCT06351332?
This trial is sponsored by Filipa Lynce, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06351332 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06351332's enrollment target sits among peer trials
78 662nd of 1224 higher than 556 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI